Depleted tumor suppressor miR-107 in plasma relates to tumor progression and is a novel therapeutic target in pancreatic cancer

Abstract This study explored decreased tumor suppressor microRNA (miRNA) plasma levels in pancreatic cancer (PCa) patients to clarify their potential as novel biomarkers and therapeutic targets. We used the microRNA array-based approach to select candidates by comparing plasma levels between PCa pat...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Taisuke Imamura, Shuhei Komatsu, Daisuke Ichikawa, Mahito Miyamae, Wataru Okajima, Takuma Ohashi, Jun Kiuchi, Keiji Nishibeppu, Hirotaka Konishi, Atsushi Shiozaki, Ryo Morimura, Hisashi Ikoma, Toshiya Ochiai, Kazuma Okamoto, Hiroki Taniguchi, Eigo Otsuji
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/9110cec5bf674e4f95c5b2b2a7305803
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9110cec5bf674e4f95c5b2b2a7305803
record_format	dspace
spelling	oai:doaj.org-article:9110cec5bf674e4f95c5b2b2a73058032021-12-02T12:32:37ZDepleted tumor suppressor miR-107 in plasma relates to tumor progression and is a novel therapeutic target in pancreatic cancer10.1038/s41598-017-06137-82045-2322https://doaj.org/article/9110cec5bf674e4f95c5b2b2a73058032017-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-06137-8https://doaj.org/toc/2045-2322Abstract This study explored decreased tumor suppressor microRNA (miRNA) plasma levels in pancreatic cancer (PCa) patients to clarify their potential as novel biomarkers and therapeutic targets. We used the microRNA array-based approach to select candidates by comparing plasma levels between PCa patients and healthy volunteers. Six down-regulated miRNAs (miR-107, miR-126, miR-451, miR-145, miR-491-5p, and miR-146b-5p) were selected. Small- and large-scale analyses using samples from 100 PCa patients and 80 healthy volunteers revealed that miR-107 was the most down-regulated miRNA in PCa patients compared with healthy volunteers (P < 0.0001; area under the receiver-operating characteristic curve, 0.851). A low miR-107 plasma level was significantly associated with advanced T stage, N stage, and liver metastasis and was an independent factor predicting poor prognosis in PCa patients (P = 0.0424; hazard ratio, 2.95). miR-107 overexpression in PCa cells induced G1/S arrest with the production of p21 and inhibited cell proliferation through the transcriptional regulation of Notch2. In vivo, the restoration and maintenance of the miR-107 plasma level significantly inhibited tumor progression in mice. Depletion of the tumor suppressor miR-107 in plasma relates to tumor progression and poor outcomes. The restoration of the plasma miR-107 level might be a novel anticancer treatment strategy for PCa.Taisuke ImamuraShuhei KomatsuDaisuke IchikawaMahito MiyamaeWataru OkajimaTakuma OhashiJun KiuchiKeiji NishibeppuHirotaka KonishiAtsushi ShiozakiRyo MorimuraHisashi IkomaToshiya OchiaiKazuma OkamotoHiroki TaniguchiEigo OtsujiNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-14 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Taisuke Imamura Shuhei Komatsu Daisuke Ichikawa Mahito Miyamae Wataru Okajima Takuma Ohashi Jun Kiuchi Keiji Nishibeppu Hirotaka Konishi Atsushi Shiozaki Ryo Morimura Hisashi Ikoma Toshiya Ochiai Kazuma Okamoto Hiroki Taniguchi Eigo Otsuji Depleted tumor suppressor miR-107 in plasma relates to tumor progression and is a novel therapeutic target in pancreatic cancer
description	Abstract This study explored decreased tumor suppressor microRNA (miRNA) plasma levels in pancreatic cancer (PCa) patients to clarify their potential as novel biomarkers and therapeutic targets. We used the microRNA array-based approach to select candidates by comparing plasma levels between PCa patients and healthy volunteers. Six down-regulated miRNAs (miR-107, miR-126, miR-451, miR-145, miR-491-5p, and miR-146b-5p) were selected. Small- and large-scale analyses using samples from 100 PCa patients and 80 healthy volunteers revealed that miR-107 was the most down-regulated miRNA in PCa patients compared with healthy volunteers (P < 0.0001; area under the receiver-operating characteristic curve, 0.851). A low miR-107 plasma level was significantly associated with advanced T stage, N stage, and liver metastasis and was an independent factor predicting poor prognosis in PCa patients (P = 0.0424; hazard ratio, 2.95). miR-107 overexpression in PCa cells induced G1/S arrest with the production of p21 and inhibited cell proliferation through the transcriptional regulation of Notch2. In vivo, the restoration and maintenance of the miR-107 plasma level significantly inhibited tumor progression in mice. Depletion of the tumor suppressor miR-107 in plasma relates to tumor progression and poor outcomes. The restoration of the plasma miR-107 level might be a novel anticancer treatment strategy for PCa.
format	article
author	Taisuke Imamura Shuhei Komatsu Daisuke Ichikawa Mahito Miyamae Wataru Okajima Takuma Ohashi Jun Kiuchi Keiji Nishibeppu Hirotaka Konishi Atsushi Shiozaki Ryo Morimura Hisashi Ikoma Toshiya Ochiai Kazuma Okamoto Hiroki Taniguchi Eigo Otsuji
author_facet	Taisuke Imamura Shuhei Komatsu Daisuke Ichikawa Mahito Miyamae Wataru Okajima Takuma Ohashi Jun Kiuchi Keiji Nishibeppu Hirotaka Konishi Atsushi Shiozaki Ryo Morimura Hisashi Ikoma Toshiya Ochiai Kazuma Okamoto Hiroki Taniguchi Eigo Otsuji
author_sort	Taisuke Imamura
title	Depleted tumor suppressor miR-107 in plasma relates to tumor progression and is a novel therapeutic target in pancreatic cancer
title_short	Depleted tumor suppressor miR-107 in plasma relates to tumor progression and is a novel therapeutic target in pancreatic cancer
title_full	Depleted tumor suppressor miR-107 in plasma relates to tumor progression and is a novel therapeutic target in pancreatic cancer
title_fullStr	Depleted tumor suppressor miR-107 in plasma relates to tumor progression and is a novel therapeutic target in pancreatic cancer
title_full_unstemmed	Depleted tumor suppressor miR-107 in plasma relates to tumor progression and is a novel therapeutic target in pancreatic cancer
title_sort	depleted tumor suppressor mir-107 in plasma relates to tumor progression and is a novel therapeutic target in pancreatic cancer
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/9110cec5bf674e4f95c5b2b2a7305803
work_keys_str_mv	AT taisukeimamura depletedtumorsuppressormir107inplasmarelatestotumorprogressionandisanoveltherapeutictargetinpancreaticcancer AT shuheikomatsu depletedtumorsuppressormir107inplasmarelatestotumorprogressionandisanoveltherapeutictargetinpancreaticcancer AT daisukeichikawa depletedtumorsuppressormir107inplasmarelatestotumorprogressionandisanoveltherapeutictargetinpancreaticcancer AT mahitomiyamae depletedtumorsuppressormir107inplasmarelatestotumorprogressionandisanoveltherapeutictargetinpancreaticcancer AT wataruokajima depletedtumorsuppressormir107inplasmarelatestotumorprogressionandisanoveltherapeutictargetinpancreaticcancer AT takumaohashi depletedtumorsuppressormir107inplasmarelatestotumorprogressionandisanoveltherapeutictargetinpancreaticcancer AT junkiuchi depletedtumorsuppressormir107inplasmarelatestotumorprogressionandisanoveltherapeutictargetinpancreaticcancer AT keijinishibeppu depletedtumorsuppressormir107inplasmarelatestotumorprogressionandisanoveltherapeutictargetinpancreaticcancer AT hirotakakonishi depletedtumorsuppressormir107inplasmarelatestotumorprogressionandisanoveltherapeutictargetinpancreaticcancer AT atsushishiozaki depletedtumorsuppressormir107inplasmarelatestotumorprogressionandisanoveltherapeutictargetinpancreaticcancer AT ryomorimura depletedtumorsuppressormir107inplasmarelatestotumorprogressionandisanoveltherapeutictargetinpancreaticcancer AT hisashiikoma depletedtumorsuppressormir107inplasmarelatestotumorprogressionandisanoveltherapeutictargetinpancreaticcancer AT toshiyaochiai depletedtumorsuppressormir107inplasmarelatestotumorprogressionandisanoveltherapeutictargetinpancreaticcancer AT kazumaokamoto depletedtumorsuppressormir107inplasmarelatestotumorprogressionandisanoveltherapeutictargetinpancreaticcancer AT hirokitaniguchi depletedtumorsuppressormir107inplasmarelatestotumorprogressionandisanoveltherapeutictargetinpancreaticcancer AT eigootsuji depletedtumorsuppressormir107inplasmarelatestotumorprogressionandisanoveltherapeutictargetinpancreaticcancer
_version_	1718394048079724544

Depleted tumor suppressor miR-107 in plasma relates to tumor progression and is a novel therapeutic target in pancreatic cancer

Ejemplares similares